Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
ROCKVILLE, Md., May 10, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Gene Therapy and Gene Editing panel discussion at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017 at 1:40 p.m. PT at the Encore Wynn in Las Vegas, NV. In addition, REGENXBIO senior management will be holding one-on-one meetings at the conference.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
